1
|
Chatzis L, Goules AV, Tzioufas AG. Can we cure Sjogren's disease? Unmet needs and raising questions in the era of Precision medicine. Curr Opin Immunol 2025; 95:102578. [PMID: 40449042 DOI: 10.1016/j.coi.2025.102578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2025] [Revised: 05/14/2025] [Accepted: 05/15/2025] [Indexed: 06/02/2025]
Abstract
The wide spectrum of Sjögren's disease (SjD) clinical manifestations coupled with its multifaceted pathogenesis has complicated drug target development, optimal clinical trial design, identification of suitable SjD subgroups, selection of appropriate outcome measures, and interpretation of treatment efficacy. Despite recent advancements in biologic treatments for autoimmune diseases, the targeted therapy(ies) for SjD remain an unmet need, with no regulatory approvals, so far. Recent large, randomized studies have suggested some patient benefits; however, reproducibility is needed, and assessment of treatment efficacy requires refinement. In this review, we explore the potential for curing SjD taking into consideration the main pathogenetic mechanisms, clinical phenotypes, and underlying endotypes. We provide an overview of current recommendations and targeted treatments, identify potential reasons for treatment failures, and propose strategies (in and out of the box) for future directions. By addressing these areas, we offer a comprehensive perspective that may inform future research and therapeutic strategies for SjD.
Collapse
Affiliation(s)
- Loukas Chatzis
- Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Research Institute for Systemic Autoimmune Diseases, 11527 Athens, Greece; Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece
| | - Andreas V Goules
- Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Research Institute for Systemic Autoimmune Diseases, 11527 Athens, Greece
| | - Athanasios G Tzioufas
- Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Research Institute for Systemic Autoimmune Diseases, 11527 Athens, Greece; Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
| |
Collapse
|
2
|
Wu J, Zhang H, Xie W, Han M, Nie Q. The necessity for prompt identification of Sjögren syndrome in instances of unexplained heart failure: A case report. Medicine (Baltimore) 2025; 104:e42451. [PMID: 40388776 PMCID: PMC12091595 DOI: 10.1097/md.0000000000042451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Accepted: 04/25/2025] [Indexed: 05/21/2025] Open
Abstract
RATIONALE Sjögren's syndrome (SS) is a highly phenotypically diverse autoimmune disorder. It has been reported that 30% to 40% of patients with SS experience systemic complications, including peripheral neuropathies, interstitial lung disease, interstitial nephritis, and lymphoma. To date, SS presenting with heart failure (HF) as the primary manifestation remains exceedingly rare. PATIENT CONCERNS We report presents a 70-year-old female patient, devoid of any cardiovascular risk factors, who experienced recurrent episodes of HF. DIAGNOSES During the course of treatment, SS was suspected based on her medical history. This suspicion was subsequently confirmed through elevated serum autoimmune antibody levels and a labial gland biopsy. INTERVENTIONS The implementation of standard HF management in conjunction with an immunosuppressive regimen. OUTCOMES At the one-year follow-up, the patient had not been readmitted for HF. LESSONS This case underscores the critical importance of early identification of HF attributable to SS and highlights the efficacy of combining immunosuppressive therapy with conventional HF treatment as the optimal approach for managing such cases.
Collapse
Affiliation(s)
- Jiao Wu
- Eye School of Chengdu University of TCM, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
| | - Hongcai Zhang
- Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
| | - Wen Xie
- Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
| | - Mingjun Han
- Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
| | - Qian Nie
- Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
| |
Collapse
|
3
|
Salvetat ML, Pellegrini F, D’Esposito F, Musa M, Tognetto D, Giglio R, Foti R, Gagliano C, Zeppieri M. Emerging Trends and Management for Sjögren Syndrome-Related Dry Eye Corneal Alterations. APPLIED SCIENCES 2025; 15:5076. [DOI: 10.3390/app15095076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2025]
Abstract
Background: Sjögren’s syndrome (SS) is a systemic autoimmune condition marked by significant dry eye disease (DED), leading to considerable corneal changes. These modifications, encompassing punctate epithelial erosions, chronic epithelial abnormalities, and corneal ulcers, significantly impact eyesight and quality of life. Progress in comprehending the corneal pathophysiology associated with SS has prompted innovative diagnostic and treatment approaches. Aim: This narrative review aims to examine developing trends in the pathogenesis, diagnostic methods, and treatment strategies for Sjögren’s syndrome-associated corneal changes. Methods: The study was based on a narrative review of the current literature available on PubMed and Cochrane from Jan 2000 to December 2024. Results: Corneal changes associated with Sjögren’s syndrome result from a multifactorial interaction of ocular surface inflammation, tear film instability, and epithelium degradation. Recent research underscores the significance of immune-mediated pathways, such as T-cell-induced inflammation and cytokine dysregulation, as crucial factors in corneal disease. Innovations in diagnostic instruments, including in vivo confocal microscopy and tear proteomics, provide earlier and more accurate identification of subclinical alterations in the corneal epithelium and stroma. Therapeutic developments concentrate on meeting the specific requirements of SS-related DED. Biological treatments, especially tailored inhibitors of interleukin-6 and tumor necrosis factor-alpha, show potential in mitigating inflammation and facilitating epithelial repair. Moreover, regenerative approaches, such as autologous serum tears and mesenchymal stem cell therapies, provide innovative methods to repair ocular surface integrity. Advanced drug delivery technologies, including nanoparticle-loaded eye drops, enhance bioavailability and therapeutic efficacy. Conclusion: Recent developments in comprehending SS-related corneal changes have transformed the management approach to precision medicine. The combination of improved diagnostics and innovative therapy approaches offers potential for reducing disease progression, maintaining corneal health, and enhancing patient outcomes. Subsequent investigations ought to concentrate on enhancing these tactics and examining their long-term safety and effectiveness. Clinicians and researchers must adopt these developments to successfully tackle the difficulties of SS-related corneal illness, providing hope for improved care and higher quality of life for those affected.
Collapse
Affiliation(s)
- Maria Letizia Salvetat
- Department of Ophthalmology, Azienda Sanitaria Friuli Occidentale, Via Montereale 24, 33170 Pordenone, Italy
| | - Francesco Pellegrini
- Department of Ophthalmology, Azienda Sanitaria Friuli Occidentale, Via Montereale 24, 33170 Pordenone, Italy
| | - Fabiana D’Esposito
- Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, London NW1 5QH, UK
- Eye Clinic, Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, 80100 Naples, Italy
| | - Mutali Musa
- Department of Optometry, University of Benin, Benin City 300238, Edo State, Nigeria
| | - Daniele Tognetto
- Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
| | - Rosa Giglio
- Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
| | - Roberta Foti
- Division of Rheumatology, A.O.U. “Policlinico-San Marco”, 95123 Catania, Italy
| | - Caterina Gagliano
- Department of Medicine and Surgery, University of Enna “Kore”, Piazza dell’Università, 94100 Enna, Italy
- Mediterranean Foundation “G.B. Morgagni”, 95125 Catania, Italy
| | - Marco Zeppieri
- Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
| |
Collapse
|
4
|
Nacar NE, Karaborklu Argut S, Unal E. Effects of exercise in primary Sjögren's syndrome: a systematic review and meta-analysis of randomized clinical trials. Disabil Rehabil 2025:1-9. [PMID: 40062666 DOI: 10.1080/09638288.2025.2474085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2024] [Revised: 02/21/2025] [Accepted: 02/24/2025] [Indexed: 03/14/2025]
Abstract
PURPOSE To systematically review the effects of exercise interventions on pain, fatigue, quality of life, disease activity, aerobic capacity, and dryness in primary Sjögren's syndrome (pSS), and to determine the most effective type of exercise. MATERIALS AND METHODS A literature search was conducted using Web of Science, PubMed/MEDLINE, ProQuest, SCOPUS, Cochrane Library, and PEDro databases. Randomized clinical trials (RCTs) examining the effects of exercise interventions in patients with pSS were included. Methodological quality was assessed using the Risk of Bias version-2 tool and PEDro scale. RESULTS Five RCTs, including 269 female patients with pSS were analyzed. High-quality studies indicated that exercise interventions significantly improved pain (p = 0.008), fatigue (p < 0.00001), quality of life (p = 0.0003), and aerobic capacity (p = 0.009) compared to controls. Sensitivity analysis indicated that resistance exercise was particularly effective, significantly improving pain (p < 0.00001), fatigue (p < 0.00001), quality of life (p < 0.00001), and disease activity (p = 0.02). CONCLUSION Exercise interventions may offer significant benefits in reducing pain and fatigue, as well as improving quality of life and aerobic capacity, in patients with pSS compared to no-treatment. Resistance exercise appears to be more effective than other exercise models.
Collapse
Affiliation(s)
- Nazli Elif Nacar
- Vocational School of Health Services, Department of Physiotherapy, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
- Graduate School of Health Sciences, Department of Physiotherapy and Rehabilitation, Hacettepe University, Ankara, Turkey
| | - Sezen Karaborklu Argut
- Faculty of Health Science, Department of Physiotherapy and Rehabilitation, Istanbul University-Cerrahpasa, Istanbul, Turkey
| | - Edibe Unal
- Faculty of Physical Therapy and Rehabilitation, Department of Physiotherapy and Rehabilitation, Hacettepe University, Ankara, Turkey
| |
Collapse
|
5
|
Chen J, Ma J, Yu J, Zhang W, Zhu Y, Feng J, Geng L, Dong X, Zhang H, Chen Y, Ning M. A comparative analysis of large language models on clinical questions for autoimmune diseases. Front Digit Health 2025; 7:1530442. [PMID: 40099036 PMCID: PMC11913117 DOI: 10.3389/fdgth.2025.1530442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2024] [Accepted: 02/14/2025] [Indexed: 03/19/2025] Open
Abstract
Background Artificial intelligence (AI) has made great strides. To explore the potential of Large Language Models (LLMs) in providing medical services to patients and assisting physicians in clinical practice, our study evaluated the performance in delivering clinical questions related to autoimmune diseases. Methods 46 questions related to autoimmune diseases were input into ChatGPT 3.5, ChatGPT 4.0, and Gemini. The responses were then evaluated by rheumatologists based on five quality dimensions: relevance, correctness, completeness, helpfulness, and safety. Simultaneously, the responses were assessed by laboratory specialists across six medical fields: concept, clinical features, report interpretation, diagnosis, prevention and treatment, and prognosis. Finally, statistical analysis and comparisons were performed on the performance of the three chatbots in the five quality dimensions and six medical fields. Results ChatGPT 4.0 outperformed both ChatGPT 3.5 and Gemini across all five quality dimensions, with an average score of 199.8 ± 10.4, significantly higher than ChatGPT 3.5 (175.7 ± 16.6) and Gemini (179.1 ± 11.8) (p = 0.009 and p = 0.001, respectively). The average performance differences between ChatGPT 3.5 and Gemini across these five dimensions were not statistically significant. Specifically, ChatGPT 4.0 demonstrated superior performance in relevance (p < 0.0001, p < 0.0001), completeness (p < 0.0001, p = 0.0006), correctness (p = 0.0001, p = 0.0002), helpfulness (p < 0.0001, p < 0.0001), and safety (p < 0.0001, p = 0.0025) compared to both ChatGPT 3.5 and Gemini. Furthermore, ChatGPT 4.0 scored significantly higher than both ChatGPT 3.5 and Gemini in medical fields such as report interpretation (p < 0.0001, p = 0.0025), prevention and treatment (p < 0.0001, p = 0.0103), prognosis (p = 0.0458, p = 0.0458). Conclusions This study demonstrates that ChatGPT 4.0 significantly outperforms ChatGPT 3.5 and Gemini in addressing clinical questions related to autoimmune diseases, showing notable advantages across all five quality dimensions and six clinical domains. These findings further highlight the potential of large language models in enhancing healthcare services.
Collapse
Affiliation(s)
- Jing Chen
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Juntao Ma
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Jie Yu
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Weiming Zhang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Yijia Zhu
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Jiawei Feng
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Linyu Geng
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Xianchi Dong
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Huayong Zhang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Yuxin Chen
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Mingzhe Ning
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| |
Collapse
|
6
|
Flood M, Ní Gabhann-Dromgoole J, Tynan G, Dillon N, Collins D, Lauder M, Sheehy E, Moriarty F, Barlow JW. Use of complementary and alternative medicine (CAM) among people living with Sjögren's: a cross-sectional survey using a modified international CAM questionnaire (I-CAM-Q). Rheumatol Int 2025; 45:55. [PMID: 39976693 PMCID: PMC11842488 DOI: 10.1007/s00296-025-05802-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2024] [Accepted: 02/01/2025] [Indexed: 02/23/2025]
Abstract
Sjögren's is a chronic autoimmune disease with diverse symptomatology, and varying patient satisfaction with management. Patients with chronic conditions are known to be higher users of complementary and alternative (CAM) practices, yet little information regarding extent of such use exists. This paper describes usage of CAM practices among people living with Sjögren's, encompassing visits to healthcare providers, CAM practitioners, self-administered CAM and self-help practices. We explored both purposes and perceived helpfulness of the various modalities utilised. 296 respondents completed an online survey administered through Sjögren's Research Ireland in 2023. An adapted form of the International Complementary and Alternative Medicine Questionnaire (I-CAM-Q) was utilised as the survey instrument. 88.5% of respondents had a formal diagnosis of Sjögren's. The majority (93.6%) were female, across all age groups. Over half (52%) of non-retired respondents were at least partially unable to work due to their diagnosis. Over half of all respondents (58.8%) listed at least one concomitant health problem. Most respondents (248, 83.8%) had used some form of CAM within the preceding 12 months. One-in-four had attended a CAM practitioner, most commonly chiropractors (8.4%) or acupuncturists (7.8%). Conventional healthcare and CAM providers were both consulted more commonly for management of chronic conditions or for well-being than for acute symptom management, although this was particularly stark for CAM consultations. 196 respondents (66.2%) reported use of self-administered CAM, predominantly vitamins/minerals or dietary supplements. 69.9% used various self-care practices, with the most reported being meditation, relaxation techniques and prayer. People living with Sjögren's attend both conventional healthcare providers and CAM practitioners to a high degree and use a diverse range of complementary therapies and practices. Health care professionals need to consider and discuss potential CAM use by this patient cohort and offer evidence-based patient education about therapies and practices encountered.
Collapse
Affiliation(s)
- Michelle Flood
- School of Pharmacy & Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
- RCSI PPI Ignite Network, Office of Research and Innovation, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Joan Ní Gabhann-Dromgoole
- School of Pharmacy & Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Gráinne Tynan
- Sjögren's Ireland Advocacy Group, Dublin, Ireland
- The SYNERG-IE Programme, School of Pharmacy & Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Niamh Dillon
- RCSI PPI Ignite Network, Office of Research and Innovation, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | | | | | | | - Frank Moriarty
- School of Pharmacy & Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - James W Barlow
- Department of Chemistry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
| |
Collapse
|
7
|
Dogru A, Gur Hatip F. Autoimmune Thyroid Disease and Sjögren Disease: Organ-Specific Disease Triggered by Systemic Autoimmunity? MEDICINA (KAUNAS, LITHUANIA) 2025; 61:287. [PMID: 40005404 PMCID: PMC11857550 DOI: 10.3390/medicina61020287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/12/2025] [Revised: 01/23/2025] [Accepted: 02/06/2025] [Indexed: 02/27/2025]
Abstract
Background and Objectives: Autoimmune thyroid diseases are more prevalent in patients diagnosed with Sjögren disease (SD) than in the general population. SD and autoimmune thyroid diseases are two distinct yet interrelated autoimmune disorders. The objective of this study was to determine the frequency of autoimmune thyroiditis (AT), autoantibody relationships, and clinical features in patients with SD. Materials and Methods: The study included 525 patients. A retrospective evaluation was conducted on the demographic data, biochemical and serological tests, and pathological data of the patients. An anti-nuclear antibody (ANA) test was performed using the indirect immunofluorescence (IIF) method using HEp-2 (HEp-2000) cells as substrate. The Schirmer test and minor salivary gland biopsy were conducted on all patients. Results: AT was detected in 167 (31.8%) of 525 patients who participated in the study. The anti-nuclear antibody (ANA) test and anti-SS-A positivity rate were higher in the AT group (p value < 0.001 and 0.002 respectively). We found that the likelihood of developing AT increased as ANA titres increased. ANA positivity titres were found to be significant at 2+, 3+, and 4+ values (odd ratios 2.41, 3.40, and 4.21, respectively). Additionally, histological examination of salivary gland biopsies revealed a significantly higher prevalence of diffuse lymphocytic infiltration in the AT group. Conclusions: AT was present in 31% of patients with SD. The presence of ANA positivity, anti-SS-A positivity, and diffuse lymphocytic infiltration appears to exert an influence on the association between these two diseases.
Collapse
Affiliation(s)
- Atalay Dogru
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Süleyman Demirel University, Isparta 32260, Turkey;
| | | |
Collapse
|
8
|
Horai Y, Kurushima S, Shimizu T, Nakamura H, Kawakami A. A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis. J Clin Med 2025; 14:568. [PMID: 39860574 PMCID: PMC11766391 DOI: 10.3390/jcm14020568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2024] [Revised: 01/13/2025] [Accepted: 01/15/2025] [Indexed: 01/27/2025] Open
Abstract
Rheumatoid arthritis (RA) is an immune-mediated disease characterized by polyarthritis that affects the small joints of the bilateral upper and lower extremities. RA shares several common clinical symptoms with Sjögren's syndrome (SS), another rheumatic disease caused by the lymphocytic infiltration of exocrine glands, with dry eye and dry mouth being the two most common symptoms. Anti-Ro/SS-A antibodies, a diagnostic biomarker of SS, are positive in patients with RA at a certain rate. The coexistence of SS and/or positivity for anti-Ro/SS-A antibodies in patients with RA influences disease activity and the effectiveness of several classes of disease-modifying antirheumatic drugs (DMARDs). Furthermore, RA, SS, and certain DMARDs, including methotrexate, are associated with the onset of lymphoproliferative disorders (LPD). In contrast, several biological DMARDs, such as tocilizumab and rituximab, are plausible options without the risk of LPD relapse. Considering the results of the studies introduced in this article, RA with SS and/or positivity for anti-Ro/SS-A antibodies could be considered a phenotype different from isolated RA from the perspective of refractoriness to DMARD therapy and LPD risk. Hence, rheumatologists should observe caution when choosing DMARDs. Further studies are needed to establish the appropriate treatment for patients with RA, SS, and/or the presence of anti-Ro/SS-A antibodies.
Collapse
Affiliation(s)
- Yoshiro Horai
- Department of Rheumatology, Sasebo City General Hospital, Sasebo 857-8511, Japan;
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; (T.S.); (A.K.)
| | - Shota Kurushima
- Department of Rheumatology, Sasebo City General Hospital, Sasebo 857-8511, Japan;
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; (T.S.); (A.K.)
| | - Toshimasa Shimizu
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; (T.S.); (A.K.)
- Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan
| | - Hideki Nakamura
- Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan;
| | - Atsushi Kawakami
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; (T.S.); (A.K.)
| |
Collapse
|
9
|
Wilson R, Townsend J, Hawkins E, Ciurtin C. Outcome Measures for Sjögren Disease-Novel Developments and Further Needs. Br J Hosp Med (Lond) 2024; 85:1-15. [PMID: 39831476 DOI: 10.12968/hmed.2024.0310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2025]
Abstract
Sjögren disease (SjD) is a systemic autoimmune disorder affecting both children and adults, with a wide range of clinical phenotypes. It remains a challenging condition to recognise and diagnose early and manage effectively. The heterogeneous nature of the presentation, variable disease course and overlapping symptoms with other autoimmune conditions often result in delayed diagnosis. This, coupled with the lack of licensed effective therapies frequently leads to suboptimal patient outcomes. Improved outcome measures are crucial for advancing our understanding of SjD pathogenesis and developing effective treatments. They can help ensure that clinical trials are accurately capturing the impact of potential therapies on the disease and the quality of life of people with SjD. Further developments are needed in the areas of age and developmentally appropriate disease and patient-reported outcome measures, with adequate sensitivity to evaluate treatment efficacy, as well as predictor biomarkers for both treatment response and poor prognostic outcomes associated with SjD. Advancing these areas will help ensure that clinical trials adequately select the most suitable SjD cohorts to treat with a certain therapy, as well as accurately reflect the impact of a certain intervention on disease activity, progression, and quality of life, ultimately leading to better care for people with SjD.
Collapse
Affiliation(s)
- Robert Wilson
- Department of Rheumatology, University College London (UCL) Hospital Foundation Trust, London, UK
| | | | - Ellie Hawkins
- Department of Rheumatology, University College London (UCL) Hospital Foundation Trust, London, UK
| | - Coziana Ciurtin
- Department of Rheumatology, University College London (UCL) Hospital Foundation Trust, London, UK
- University College London (UCL) Centre for Adolescent Rheumatology, London, UK
| |
Collapse
|
10
|
Lee CN, Wafa HA, Murphy G, Galloway J, Mahroo OA, Jackson TL. Novel electroretinography devices to detect hydroxychloroquine retinopathy: study protocol for a diagnostic accuracy and feasibility study. BMJ Open Ophthalmol 2024; 9:e001898. [PMID: 39719323 PMCID: PMC11683940 DOI: 10.1136/bmjophth-2024-001898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Accepted: 11/05/2024] [Indexed: 12/26/2024] Open
Abstract
INTRODUCTION Annual screening for hydroxychloroquine (HCQ) retinopathy is recommended, and electroretinography (ERG) is considered a gold-standard test, but there are screening shortfalls and standard ERG is burdensome and has limited availability. Newer, portable ERG devices using skin-based electrodes may increase screening capacity but need validation. This study aims to determine initial device accuracies and feasibility of further research. METHODS AND ANALYSIS Prospective diagnostic device accuracy and feasibility study comparing novel ERG devices to standard screening tests. Three groups of 35 participants on HCQ, categorised by HCQ retinopathy (definite, possible and no retinopathy), and 35 healthy control participants, recruited by consecutive sampling, will have full field and multifocal ERG index tests, delivered using skin-contact electrodes by two devices-RETEval full-field and UTAS multifocal ERG, both manufactured by LKC Technologies (Gaithersburg, Maryland, USA), compared with spectral-domain optical coherence tomography and autofluorescence reference tests graded by two masked, independent retinal specialists. Eligible HCQ participants will either have diagnosed HCQ retinopathy or be eligible for screening per UK guidelines. Healthy control participants will have no prior HCQ exposure and be of similar age and sex to HCQ participants. Primary outcome is device-specific sensitivity and specificity. Secondary outcomes include the effect of dilation on device outputs, analysis of discriminatory waveforms, device acceptability and recruitment rate. Safety outcomes include adverse and serious adverse events and device events. ETHICS AND DISSEMINATION Cambridge East ethics committee gave a favourable opinion (24/EE/0011, 23/02/2024). Results will be published in a peer-reviewed ophthalmology journal. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT06035887.
Collapse
Affiliation(s)
- Chan Ning Lee
- Faculty of Life Sciences and Medicine, King's College London, London, UK
- Ophthalmology, King's College Hospital, London, UK
| | - Hatem A Wafa
- Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
| | - George Murphy
- Faculty of Life Sciences and Medicine, King's College London, London, UK
- Ophthalmology, King's College Hospital, London, UK
| | - James Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK
- Rheumatology, King's College Hospital, London, London, UK
| | - Omar A Mahroo
- Institute of Ophthalmology, University College London, London, UK
- Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK
| | - Timothy L Jackson
- Faculty of Life Sciences and Medicine, King's College London, London, UK
- Ophthalmology, King's College Hospital, London, UK
| |
Collapse
|
11
|
Abisheva S, Rutskaya-Moroshan K, Nuranova G, Batyrkhan T, Abisheva A. Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities? MEDICINA (KAUNAS, LITHUANIA) 2024; 60:1171. [PMID: 39064600 PMCID: PMC11279047 DOI: 10.3390/medicina60071171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Revised: 07/14/2024] [Accepted: 07/15/2024] [Indexed: 07/28/2024]
Abstract
Background and Objectives: The coronavirus disease of 2019 (COVID-19) pandemic has posed a serious threat to humanity and is considered a global health emergency. Antimalarial drugs (ADs) have been used in the treatment of immuno-inflammatory arthritis (IIA) and coronavirus infection (COVID-19). The aim of this review is to analyze the current knowledge about the immunomodulatory and antiviral mechanisms of action, characteristics of use, and side effects of antimalarial drugs. Material and Methods: A literature search was carried out using PubMed, MEDLINE, SCOPUS, and Google Scholar databases. The inclusion criteria were the results of randomized and cohort studies, meta-analyses, systematic reviews, and original full-text manuscripts in the English language containing statistically confirmed conclusions. The exclusion criteria were summary reports, newspaper articles, and personal messages. Qualitative methods were used for theoretical knowledge on antimalarial drug usage in AIRDs and SARS-CoV-2 such as a summarization of the literature and a comparison of the treatment methods. Results: The ADs were considered a "candidate" for the therapy of a new coronavirus infection due to mechanisms of antiviral activity, such as interactions with endocytic pathways, the prevention of glycosylation of the ACE2 receptors, blocking sialic acid receptors, and reducing the manifestations of cytokine storms. The majority of clinical trials suggest no role of antimalarial drugs in COVID-19 treatment or prevention. These circumstances do not allow for their use in the treatment and prevention of COVID-19. Conclusions: The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for COVID-19. Furthermore, the need for high doses in the treatment of viral infections increases the likelihood of gastrointestinal side effects, the prolongation of QT, and retinopathy. Large randomized clinical trials (RCTs) have refuted the fact that there is a positive effect on the course and results of COVID-19.
Collapse
Affiliation(s)
- Saule Abisheva
- Department of Family Medicine №1, NJSC “Astana Medical University”, Astana 010000, Kazakhstan; (S.A.); (T.B.); (A.A.)
| | - Kristina Rutskaya-Moroshan
- Department of Family Medicine №1, NJSC “Astana Medical University”, Astana 010000, Kazakhstan; (S.A.); (T.B.); (A.A.)
| | - Gulnaz Nuranova
- Department of Children’s Diseases with Courses in Pulmonology and Nephrology, NJSC “Astana Medical University”, Astana 010000, Kazakhstan;
| | - Tansholpan Batyrkhan
- Department of Family Medicine №1, NJSC “Astana Medical University”, Astana 010000, Kazakhstan; (S.A.); (T.B.); (A.A.)
| | - Anilim Abisheva
- Department of Family Medicine №1, NJSC “Astana Medical University”, Astana 010000, Kazakhstan; (S.A.); (T.B.); (A.A.)
| |
Collapse
|